BiotechTube
Carrick Therapeutics

Carrick Therapeutics

Dublin, Ireland· Est.
carricktherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $366M

Overview

Carrick Therapeutics is an Ireland-founded, clinical-stage oncology biotech with a strategic shift to a Boston headquarters, indicating a focus on the U.S. biopharma ecosystem. Its lead asset, samuraciclib (a CDK7 inhibitor), is in multiple Phase 2 trials for HR+/HER2- advanced breast cancer, showing a combination-focused development strategy. The company also has an early-stage, first-in-class CDK12/13 inhibitor, CT7439, in Phase 1, diversifying its pipeline. Carrick operates as a private company, collaborating with major pharma partners to advance its programs.

Oncology

Technology Platform

Focused expertise in cyclin-dependent kinase (CDK) biology, developing selective inhibitors of CDK7 and CDK12/13 to target transcription and DNA damage response in cancer cells, with a core strategy of developing these agents in combination with standard-of-care therapies.

Funding History

6
Total raised:$366M
Series C$87M
Series C$25M
Series B$95M
Series B$95M

Opportunities

The large, unmet need in HR+ advanced breast cancer post-CDK4/6 inhibitor failure represents a multi-billion dollar market opportunity for an effective therapy like samuraciclib.
The first-in-class mechanism of CT7439 (CDK12/13 inhibition) offers a potential foothold in precision oncology for cancers with specific vulnerabilities, such as those with homologous recombination deficiencies.

Risk Factors

High clinical development risk as both lead programs are in mid-to-early stages and must prove efficacy and safety in larger trials.
Intense competition in the CDK inhibitor and breast cancer spaces threatens market differentiation.
Financial risk is inherent as a private, pre-revenue company dependent on fundraising in a volatile capital environment.

Competitive Landscape

Samuraciclib faces competition from other novel CDK inhibitors in development (e.g., targeting CDK2, CDK4/6) and from other classes of drugs targeting endocrine resistance in breast cancer. The CDK12/13 inhibitor space is less crowded but still emerging, with other biotechs exploring similar mechanisms. Carrick's combination-focused strategy with major pharma partners is a key differentiator.

More companies in Small Molecule Drugs →More companies in Ireland →